Immunoconjugates

"Immunoconjugates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.

Descriptor ID	D018796
MeSH Number(s)	D12.776.124.790.651.114.580 D12.776.377.715.548.114.580
Concept/Terms	Immunoconjugates Immunoconjugates Immunoconjugate Radioimmunoconjugates Radioimmunoconjugates Radioimmunoconjugate

Below are MeSH descriptors whose meaning is more general than "Immunoconjugates".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Immunoconjugates [D12.776.124.790.651.114.580]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Immunoconjugates [D12.776.377.715.548.114.580]

Below are MeSH descriptors whose meaning is more specific than "Immunoconjugates".

Immunoconjugates
Abatacept
Immunotoxins

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Immunoconjugates" by people in this website by year, and whether "Immunoconjugates" was a major or minor topic of these publications.

Bar chart showing 50 publications over 21 distinct years, with a maximum of 8 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1998	1	0	1
1999	1	0	1
2000	2	1	3
2001	1	0	1
2006	1	0	1
2007	0	2	2
2008	1	0	1
2012	3	0	3
2014	3	1	4
2015	2	1	3
2016	2	0	2
2017	5	0	5
2018	1	1	2
2019	1	1	2
2020	2	0	2
2021	8	0	8
2022	2	0	2
2023	2	0	2
2024	1	1	2
2025	1	0	1

Below are the most recent publications written about "Immunoconjugates" by people in Profiles.

Zarrabi KK, Saxena A, Mouw KW, Koshkin VS, Friedlander T. Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma. Am Soc Clin Oncol Educ Book. 2025 Jan; 45(2):e471924.

View in: PubMed
Zeng L, Zhu Y, Cui X, Chi J, Uddin A, Zhou Z, Song X, Dai M, Cristofanilli M, Kalinsky K, Wan Y. Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs. Adv Sci (Weinh). 2024 10; 11(40):e2400757.

View in: PubMed
Vlachou E, Mamtani R, Hahn NM, Iii BJ, Hoffman-Censits J, Nimgaonkar V. Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin. Clin Genitourin Cancer. 2024 06; 22(3):102090.

View in: PubMed
Fast J, Christian T, Crul M, Jiskoot W, Nejadnik MR, Medina A, Radwick A, Sreedhara A, Tole H. Use of Closed System Transfer Devices (CSTDs) with Protein-Based Therapeutic Drugs-A Non-Solution for a Non-Problem? J Pharm Sci. 2024 02; 113(2):298-305.

View in: PubMed
Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, Wu K. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023 08 28; 16(1):100.

View in: PubMed
Hingorani P, Zhang W, Zhang Z, Xu Z, Wang WL, Roth ME, Wang Y, Gill JB, Harrison DJ, Teicher BA, Erickson SW, Gatto G, Kolb EA, Smith MA, Kurmasheva RT, Houghton PJ, Gorlick R. Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther. 2022 08 02; 21(8):1318-1325.

View in: PubMed
Nicol? E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, Cristofanilli M, Curigliano G. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022 May; 106:102395.

View in: PubMed
Choi W, Lombardo K, Patel S, Epstein G, Feng M, Gabrielson A, Hahn NM, Hoffman-Censits J, McConkey D, Bivalacqua TJ, Matoso A, Kates M. A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Gu?rin-exposed Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 02; 81(2):138-142.

View in: PubMed
Ou C, Li C, Zhang R, Yang Q, Zong G, Dai Y, Francis RL, Bournazos S, Ravetch JV, Wang LX. One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling. Bioconjug Chem. 2021 08 18; 32(8):1888-1897.

View in: PubMed
Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, Evens AM, Pro B. A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV?+?lymphomas. Leuk Lymphoma. 2021 12; 62(14):3493-3500.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement